Mounjaro (tirzepatide) costs $1,069–$1,112 per month at list price — but what you pay depends almost entirely on your insurance situation and why it was prescribed. If you have type 2 diabetes, Mounjaro is FDA-approved and often covered. If you’re prescribed it off-label for weight loss without a diabetes diagnosis, you face a different cost landscape entirely — one where Zepbound, the weight-loss-approved version of the same drug, is often the smarter financial choice. SunnyPharma breaks down every cost scenario.
With commercial insurance for type 2 diabetes, the Mounjaro Savings Card can bring your cost to as low as $25/month. Without insurance for weight loss, Mounjaro has no manufacturer self-pay program — retail costs run $995–$1,300/month. The same active ingredient (tirzepatide) is available as Zepbound through LillyDirect at $299–$449/month for weight-loss patients paying cash. Compounded tirzepatide runs $179–$349/month.
Mounjaro vs. Zepbound — the key cost distinction: Mounjaro and Zepbound contain identical active ingredients at identical doses. The difference is FDA indication: Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight loss. Eli Lilly’s self-pay program (LillyDirect, $299–$449/month) covers Zepbound only — not Mounjaro. If you are seeking tirzepatide for weight loss without insurance, asking your prescriber for a Zepbound prescription instead of Mounjaro gives you access to a significantly cheaper legitimate path.
Mounjaro Cost Without Insurance
Unlike Novo Nordisk, which created a dedicated self-pay program for Wegovy at $349/month, Eli Lilly has not launched an equivalent Mounjaro cash-pay program. Without insurance, a Mounjaro prescription for weight loss has no manufacturer escape route — you pay retail.
| Access route | Monthly cost | Notes |
|---|---|---|
| Retail pharmacy (no assistance) | $995–$1,300 | Varies by pharmacy and location. All doses carry same list price. |
| GoodRx coupon (retail) | ~$859–$1,112 | Reduces retail price modestly. Cannot combine with savings card. |
| Zepbound via LillyDirect (same drug) | $299–$449 | Requires Zepbound Rx (not Mounjaro Rx). KwikPen multi-dose device. Cash-pay only. Valid prescription required. |
| Compounded tirzepatide (telehealth) | $179–$349 | Legal while tirzepatide remains on FDA shortage list. Not FDA-approved. See section below. |
The practical takeaway: if you are uninsured and want tirzepatide for weight loss, a Mounjaro prescription is the most expensive option. Switching to a Zepbound prescription (same drug, weight-loss FDA approval, LillyDirect self-pay program) or choosing compounded tirzepatide are both materially cheaper. Discuss which is appropriate with your prescriber.
Mounjaro vs. Zepbound Cost — Same Drug, Different Price
| Mounjaro | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide (identical) |
| FDA indication | Type 2 diabetes | Obesity / weight loss + OSA |
| List price | ~$1,069–$1,112/mo | ~$1,060/mo (pens) |
| Manufacturer self-pay program | None for weight loss | LillyDirect: $299–$449/mo (KwikPen) |
| Medicare GLP-1 Bridge (Jul 1, 2026) | Not included | Zepbound KwikPen only — $50/mo |
| Savings card (commercial insurance) | $25/mo (diabetes indication) | $25/mo (weight loss indication) |
| Best for uninsured weight-loss patient | No — no self-pay program | Yes — LillyDirect available |
Mounjaro Cost With Insurance
Insurance coverage for Mounjaro depends heavily on why it is prescribed:
- Type 2 diabetes (FDA-approved use): Most commercial plans cover Mounjaro for diabetes with prior authorization. With the Mounjaro Savings Card, eligible commercially insured patients pay as little as $25/month.
- Off-label weight loss (no diabetes diagnosis): Most insurance plans will not cover Mounjaro for weight loss. Coverage denials are common and expected. Your insurer may redirect you to Zepbound, which is FDA-approved for weight loss and may have different formulary placement.
- Medicare Part D: May cover Mounjaro for type 2 diabetes with prior authorization. Cannot cover Mounjaro for weight loss alone. The Mounjaro Savings Card cannot be used with Medicare. Starting July 1, 2026, the Medicare GLP-1 Bridge covers Zepbound KwikPen for obesity — not Mounjaro.
- Medicaid: Most state programs cover Mounjaro for type 2 diabetes. Coverage for weight loss without diabetes is rare. Savings card cannot be used with Medicaid.
Mounjaro Savings Card — Who Qualifies
The Mounjaro Savings Card reduces out-of-pocket cost to as little as $25/month for eligible commercially insured patients. Key terms:[1]
- Requires commercial (employer or marketplace) insurance that covers Mounjaro
- Not available to patients with Medicare, Medicaid, TRICARE, VA, or other government insurance — federal law prohibits this
- Program scheduled through December 31, 2026; subject to modification by Eli Lilly
- Enroll at mounjaro.com or call Lilly Support Services at 1-800-545-5979
If your insurance covers Mounjaro for diabetes and you qualify for the savings card, this is your lowest-cost path. If your insurance does not cover Mounjaro — or covers it only for diabetes and you need it for weight loss — the savings card does not help. In that case, a Zepbound prescription with LillyDirect is the next option.
Compounded Tirzepatide — Cost and Legal Status
Compounded tirzepatide runs $179–$349/month through telehealth platforms in 2026. It is currently legal because the FDA has tirzepatide on its drug shortage list — compounding under shortage exemption is permitted under Section 503A of the Food, Drug, and Cosmetic Act. However, this legal basis is shortage-dependent:[2]
- If the FDA removes tirzepatide from the shortage list, 503B outsourcing facilities must stop compounding within 60 days
- 503A pharmacies may continue compounding with a prescriber-documented personalization need even after the shortage resolves
- Ask your prescriber about continuity planning before starting a compounded tirzepatide program
Compounded tirzepatide is not FDA-approved, not bioequivalence-tested against Mounjaro or Zepbound, and not covered by insurance or the Medicare GLP-1 Bridge. Verify any compounding pharmacy at nabp.pharmacy.
Patient Assistance for Mounjaro
Eli Lilly offers a patient assistance program for qualifying uninsured or underinsured patients who cannot afford Mounjaro. Eligibility is income-based. To inquire: call Lilly Support Services at 1-800-545-5979 or visit lilly.com/lillydirect. Independent resources NeedyMeds and RxAssist can also screen eligibility.
Frequently Asked Questions About Mounjaro Cost
How much does Mounjaro cost per month in 2026?
Mounjaro’s list price is $1,069–$1,112/month for a 28-day supply of four pens, regardless of dose. With commercial insurance and the Mounjaro Savings Card, eligible patients pay as little as $25/month. Without insurance, retail prices run $995–$1,300/month with no manufacturer self-pay program for weight loss. Zepbound (the same drug, tirzepatide) is available through LillyDirect for $299–$449/month for weight-loss patients paying cash.
How much does Mounjaro cost without insurance?
Without insurance, Mounjaro costs $995–$1,300/month at retail pharmacies. GoodRx coupons reduce this modestly to approximately $859–$1,112/month. Unlike Wegovy, Mounjaro has no manufacturer self-pay program for weight-loss patients. If you want tirzepatide for weight loss without insurance, asking your prescriber for Zepbound instead gives you access to LillyDirect pricing at $299–$449/month — the same drug at a fraction of the retail Mounjaro price. Compounded tirzepatide runs $179–$349/month.
Is Mounjaro or Zepbound cheaper without insurance?
Zepbound is significantly cheaper for uninsured weight-loss patients. Mounjaro has no manufacturer self-pay option for weight loss — retail prices are $995–$1,300/month. Zepbound (identical drug) is available through LillyDirect at $299–$449/month. The only reason to choose Mounjaro over Zepbound without insurance is if your prescriber has a specific clinical reason — otherwise Zepbound is the financially rational choice for the same medication.
What is the Mounjaro Savings Card and who qualifies?
The Mounjaro Savings Card is Eli Lilly’s copay assistance program for commercially insured patients. It reduces monthly cost to as little as $25. Eligibility requires commercial insurance that covers Mounjaro — it does not apply to Medicare, Medicaid, TRICARE, VA, or other government insurance. Enroll at mounjaro.com or call 1-800-545-5979. The program runs through December 31, 2026, subject to Lilly modification.
Does Medicare cover Mounjaro in 2026?
Medicare Part D may cover Mounjaro when prescribed for type 2 diabetes, subject to prior authorization and plan formulary. Medicare cannot cover Mounjaro prescribed solely for weight loss — this is a statutory prohibition. The Medicare GLP-1 Bridge (effective July 1, 2026) does not cover Mounjaro. It covers only the Zepbound KwikPen for obesity treatment, at $50/month through December 31, 2027. If you have Medicare and want tirzepatide for weight loss, Zepbound KwikPen through the Bridge is the only Medicare pathway.
Does insurance cover Mounjaro for weight loss?
Generally no — not if Mounjaro is prescribed off-label for weight loss without a type 2 diabetes diagnosis. Most commercial plans cover Mounjaro for its FDA-approved use (type 2 diabetes) but deny coverage for weight loss alone. If your goal is weight loss and your insurer denies Mounjaro, ask whether they cover Zepbound for weight loss — it is FDA-approved for that indication and may have different formulary placement on your plan.
Is there a generic version of Mounjaro?
No. As of 2026, there is no FDA-approved generic version of Mounjaro or tirzepatide in the United States. Eli Lilly holds patent protection on tirzepatide. Compounded tirzepatide is not a generic — it has not undergone FDA bioequivalence review. If someone is selling “generic Mounjaro,” it is not FDA-approved and should not be purchased.
Is compounded tirzepatide legal in 2026?
As of June 2026, yes — tirzepatide remains on the FDA drug shortage list, making compounding legal under 503A and 503B pharmacy rules. If the FDA removes tirzepatide from the shortage list, 503B outsourcing facilities must stop compounding within 60 days; 503A pharmacies may continue with a prescriber-documented personalization need. Ask your prescriber about continuity planning before starting. Verify any compounding pharmacy at nabp.pharmacy.
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound contain identical active ingredients (tirzepatide) at identical dose strengths. The only differences are FDA indication (Mounjaro = type 2 diabetes; Zepbound = obesity and obstructive sleep apnea) and the self-pay pricing available through each. Because Zepbound has the weight-loss FDA approval, it qualifies for LillyDirect self-pay pricing ($299–$449/month) and the Medicare GLP-1 Bridge ($50/month) — benefits not available for Mounjaro when prescribed for weight loss.
How we reviewed this article:
Pricing sourced from Eli Lilly’s official pricing information page, LillyDirect program terms, and GoodRx retail data (June 2026). FDA indication and shortage status sourced from FDA drug shortage database and prescribing information. Compounded tirzepatide legal status sourced from FDA 503A/503B guidance.
Read our editorial policy →Sources & References
- Eli Lilly. Mounjaro Savings Card Program Terms. 2026. mounjaro.com
- FDA. Drug Shortage Database — Tirzepatide. 2026. accessdata.fda.gov
- Eli Lilly. Mounjaro List Price Information. 2026. pricinginfo.lilly.com
- Eli Lilly. LillyDirect — Zepbound Self-Pay Program. 2026. lilly.com/lillydirect
- GoodRx. Mounjaro Prices and Coupons 2026. goodrx.com
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge Program. May 2026. cms.gov
- NABP. Verified Pharmacy Program. 2026. nabp.pharmacy
- NeedyMeds. Eli Lilly Patient Assistance Programs. 2026. needymeds.org